Short answer
Tvardi Therapeutics, Inc. (TVRD) filed its Q1 2026 10-Q quarterly report on May 8, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$7M
- −38.7% YoY
- EPS (diluted)
- −$0.73
- +77.3% YoY
Source: XBRL data from the Tvardi Therapeutics, Inc. (TVRD) Q1 2026 10-Q on SEC EDGAR. USD.
Tvardi Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no products approved or sales generated
- Net loss $6.8M vs $9.6M YoY; operating-margin figures not provided
- TTI-109 highest clinical spending; TTI-101 spending focused on HCC trial
- Cash $19.9M and short-term investments $5.1M at March 31, 2026
- Topline TTI-109 data expected June 2026; additional funding required amid going-concern doubt
Risk Factors
- No risk-factors section provided in the submitted filing text
- No newly added, updated, regulatory, operational, competitive, market, or financial risks identifiable
- Rule 10b5-1 arrangements: none adopted or terminated during three months ended March 31, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tvardi Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.